Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Latest Information Update: 27 May 2024
At a glance
- Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
- Indications Craniopharyngioma
- Focus Therapeutic Use
- 22 May 2024 Status changed from recruiting to active, no longer recruiting.
- 25 Jan 2024 Planned primary completion date changed from 1 Oct 2023 to 1 Oct 2024.
- 08 Jun 2021 Results (n=16) evaluating the efficacy of BRAF/MEK inhibition in patients (pts) with previously untreated papillary craniopharyngiomas presented at the 57th Annual Meeting of the American Society of Clinical Oncology